Comparison · NCT01749904-ba62c8cd
BOL-303259-X vs Timolol: Response Rate - IOP Reduction ≥ 25%
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. BOL-303259-X vs Timolol: Response Rate - IOP Reduction ≥ 25%. Trial comparisons, record NCT01749904-ba62c8cd. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT01749904-ba62c8cd
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.349 | 0.296 | 0.406 | wilson | |
| Risk in group 2 | 0.195 | 0.137 | 0.271 | wilson | |
| Risk difference, group 1 minus group 2 | 0.153 | 0.0608 | 0.235 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 1.78 | 1.22 | 2.61 | log | |
| Odds ratio, group 1 over group 2 | 2.2 | 1.34 | 3.61 | log | |
| Number needed to treat, for one more participant with the outcome on BOL-303259-X than on Timolol | 6.53 | 4.26 | 16.5 | from the risk difference interval |
Source ClinicalTrials.gov
Groups2
Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | BOL-303259-X | BOL-303259-X ophthalmic solution QD (PM) and vehicle QD (AM) administered for 3 months (Visit 6) into the study eye(s).~BOL-303259-X: Topical ocular BOL-303259-X will be administered QD in the evening and its vehicle administered QD in the morning for 3 months (visit 6).~BOL-303259-X: All participants will receive topical ocular BOL-303259-X QD in the evening for an additional 9 months from Visit 6 through Visit 9 (1 year) | 99 | 284 | OG000 |
| Group 2 | Timolol | Timolol maleate ophthalmic solution, 0.5%, administered BID for 3 months (Visit 6) into study eye(s).~Timolol: Timolol will be administered BID once in the morning and once in the evening for 3 months (Visit 6)~BOL-303259-X: All participants will receive topical ocular BOL-303259-X QD in the evening for an additional 9 months from Visit 6 through Visit 9 (1 year) | 26 | 133 | OG001 |
Source ClinicalTrials.gov
Outcome
- Type
- SECONDARY
- Title
- Response Rate - IOP Reduction ≥ 25%
- Description
- Percentage of participants with IOP reduction ≥ 25% consistently at all 9 time points in the first 3 months
- Time frame
- 8 AM, 12 PM, and 4 PM at Visit 4(Week 2), Visit 5 (Week 6), and Visit 6 (Month 3).
- Population
- Intent-to-treat with LOCF
Source ClinicalTrials.gov
Trial
- Title
- Comparing Safety and Efficacy of BOL-303259-X With Timolol Maleate in Subjects With Open-Angle Glaucoma or Ocular Hypertension
- NCT number
- NCT01749904
- Phases
- PHASE3
- Conditions
- Open-Angle Glaucoma, Ocular Hypertension
- Interventions
- BOL-303259-X, Timolol, BOL-303259-X
- Lead sponsor
- Bausch & Lomb Incorporated
- Results first posted
- 2018-11-07
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT01749904?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT01749904-ba62c8cd